FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.
Fifth Lilly Oncology on Canvas Art Competition invites all touched by cancer
- Details
- Category: Eli Lilly and Company
Get your canvases, paintbrushes and cameras ready - the subject is cancer and you are the storyteller. Lilly Oncology and the National Coalition for Cancer Survivorship (NCCS) announced the launch of the 2012 Lilly Oncology On Canvas: Expressions of a Cancer Journey Art Competition and Exhibition.
Sanofi fourth-quarter and full-year net sales
- Details
- Category: Sanofi
In the fourth quarter of 2011, Sanofi generated sales of €8,508 million, up 8.8% on a reported basis. Exchange rate movements had a negative effect of 0.4 percentage points.
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
- Details
- Category: Bristol-Myers Squibb
Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix® (clopidogrel bisulfate) patent infringement case against Apotex.
Roche in 2011: Strong results and positive outlook
- Details
- Category: Roche
The Roche Group posted strong operating results in a challenging market in 2011. Core operating profit grew faster than sales, and Core Earnings per Share increased by 11% at constant exchange rates (-4% in Swiss francs).
AstraZeneca fourth quarter and full year results 2011
- Details
- Category: AstraZeneca
AstraZeneca's revenue in the fourth quarter was unchanged at CER and on an actual basis as exchange rate movements were neutral to reported revenue. Adjusted for the disposal of Astra Tech, revenue growth was 2 percent.
Pfizer reports fourth-quarter and full-year 2011 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2011. Fourth-quarter 2011 revenues were $16.7 billion, a decrease of 4% compared with $17.4 billion in the year-ago quarter, which reflects an operational decline of $765 million, or 5%, and the favorable impact of foreign exchange of $157 million, or 1%.
More Pharma News ...
- Novartis extends commitment to help achieve final elimination of leprosy
- Amgen's Full Year 2011 Revenue Increased 4 Percent to $15.6 Billion
- Alzheimer's Challenge 2012: seeking new tools to help improve Alzheimer's care
- Bristol-Myers Squibb delivers solid fourth quarter capping a year highlighted by new product approvals
- Amgen to Acquire Micromet
- Novartis delivers strong underlying financial performance in 2011
- Abbott reports double-digit ongoing earnings-per-share growth in fourth quarter and full-year 2011